APA (7th ed.) Citation

Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., . . . Shustov, A. (2017). Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood, 130(25), 2709. https://doi.org/10.1182/blood-2017-05-780049

Chicago Style (17th ed.) Citation

Pro, Barbara, et al. "Five-year Results of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma." Blood 130, no. 25 (2017): 2709. https://doi.org/10.1182/blood-2017-05-780049.

MLA (9th ed.) Citation

Pro, Barbara, et al. "Five-year Results of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma." Blood, vol. 130, no. 25, 2017, p. 2709, https://doi.org/10.1182/blood-2017-05-780049.